Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.
about
Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based TherapyPreventing stem cell transplantation-associated viral infections using T-cell therapyAntiviral T-cell therapyCombining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in miceGVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppressionInduction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.The role of B7 family molecules in hematologic malignancyStrategies in haploidentical stem cell transplantation in adults.Acute graft-versus-host disease: from the bench to the bedside.Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T CellsChallenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.Haploidentical transplantation for leukemia.Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes.Clinical tolerance in allogeneic hematopoietic stem cell transplantation.Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.The expanding frontier of hematopoietic cell transplantation.T cell depletion in paediatric stem cell transplantation.The current role of T cell depletion in paediatric stem cell transplantation.T-cell costimulatory blockade in organ transplantation.Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers."No donor"? Consider a haploidentical transplantAccelerating immune reconstitution after hematopoietic stem cell transplantation.Haploidentical hematopoietic stem-cell transplantation in adults.FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance.Advances in haploidentical stem cell transplantation.Ex Vivo Costimulatory Blockade to Generate Regulatory T Cells From Patients Awaiting Kidney Transplantation.CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity.Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules.Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation.
P2860
Q26774657-A276F3AD-BD36-4432-9973-41FB77E221A1Q26801365-79CBAF16-5D4F-4A9C-85C3-A734014A7BFAQ27028006-602649D5-EF55-4AFF-BBF7-831457E0124AQ33862876-979833E6-2D87-4677-A031-10F4BADA7D17Q34276582-EF2EB98A-0264-4333-8ED3-FBB5972DA524Q34450497-468649E1-0D11-4B6C-845F-43298CC6E569Q35396480-2162EEC4-CC08-4C44-95E9-BC9E0BA2236AQ35575711-3C76A0AC-7AC1-4268-B165-1CA1BE5DCE6AQ35965199-EF75FFC1-111E-49EC-8F4B-102F773983EAQ36584814-0730A6A7-9EE6-48F0-A2BD-F2BFB3F92FECQ37418956-337CDC6B-D761-4117-8F98-CCD1E8179C05Q37420496-6A8406DC-DF41-4DE4-ACA6-D3F963DA3A6BQ37535106-EBB36D26-28A2-447B-8C10-06DC49789E88Q37687412-778C4B13-4149-415B-AD5D-8AFB031ADB30Q37770075-A9A6D2A8-F932-4F31-9619-AE9CE830FD93Q37863035-3B0B6E68-D1C4-4482-866B-934BD405318FQ37864697-909DF923-BACF-43EA-BD17-A2F9D385DEB6Q38003477-46265F6F-A144-48FE-B1A9-DA0E07CDB6B0Q38032255-5C205B4A-7841-49B4-B3D8-9ADB1E737F02Q38097916-1B7D07A8-8048-4A4D-BDAA-130A087D56FAQ38110308-5431C8CF-701C-47BD-B367-04BDCC473D41Q38168010-08933194-5332-4356-AFAC-505F3ABD301CQ38190856-DC99112D-5ACE-4902-89A7-9FC97C14B304Q38259420-74F475D9-69B5-4E9B-A195-ACF7FD3D79B1Q38288125-1821DFEE-88D8-4656-96AA-50DD662418E3Q38802389-6E1B30BD-ECD2-4D91-BDAF-3FABAAD27EF1Q39066197-2EF06B79-E493-4BCF-B965-3C197C68A693Q39799610-4BD2661E-E9AA-41FD-8B56-EA7244B5C0C1Q40083199-3B8A285E-F7D6-4D48-8536-F6FC87124D67Q41916538-8562F37A-9879-44B9-812B-C78F24634BE4Q42009496-9C6CA9EB-4E0B-4B2C-B151-3850360DCB55Q43655192-EF67453C-478A-4742-A8F7-F0421F3E043DQ51759591-DE2E3DEA-3CED-4E5B-BD16-036793848196Q52888768-D69B6F5C-702F-429A-9753-8CA7059DE5AE
P2860
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Outcome of alloanergized haplo ...... results of 2 phase 1 studies.
@en
type
label
Outcome of alloanergized haplo ...... results of 2 phase 1 studies.
@en
prefLabel
Outcome of alloanergized haplo ...... results of 2 phase 1 studies.
@en
P2093
P2860
P1433
P1476
Outcome of alloanergized haplo ...... results of 2 phase 1 studies.
@en
P2093
Dongin Yuk
Eva C Guinan
Jeff K Davies
John G Gribben
Lee M Nadler
Lisa L Brennan
P2860
P304
P356
10.1182/BLOOD-2008-03-143636
P407
P577
2008-07-10T00:00:00Z